

Enhancing Immunity Against Melanoma using Type I Interferon

by

Rachael Zemek

BSc Biomedical Science and Biological Sciences

This thesis is presented for the Honours Degree in Molecular Biology at
Murdoch University

School of Veterinary and Life Sciences

Murdoch University

Western Australia

November 2013



Declaration

I declare this thesis is my own account of my research and contains as its main content, work which has not been previously submitted for a degree at any tertiary educational institution.

.....
Rachael Marie Zemek

Word Count

Abstract:	292
1. Introduction:	6,366
2. Materials and methods:	3,674
3. Results:	6,460
4. Discussion:	4,870
5. Conclusion:	580
 Total	 22,242

Formatting

Document styled as specified by John Wiley and Sons author guide.

Referencing style follows format of journal 'Immunology'.

Abstract

Melanoma is an aggressive cancer, which when diagnosed in the late stages has a median survival rate of 6 months. The current gold-standard for adjuvant therapy is high doses of the type I interferon (IFN)- α 2, which prolongs disease free survival, but not overall survival. This high-dose therapy has many serious side-effects, resulting in doses to be lowered to sub-therapeutic levels. It is not clear how IFN- α 2 acts to treat melanoma, however it is accepted that immune enhancement is involved. The two main type I IFN families, IFN- α and IFN- β , signal via the same receptor, however they have been found to be functionally different. Of the IFN- α family, 13 subtypes have been discovered and there is evidence that each is functionally unique. This project explores the therapeutic efficacy of seven type I IFN subtypes, including IFN- α 2 and IFN- β , in treating melanoma. To test efficacy, a model of DNA therapy to administer plasmids encoding the IFN subtypes was combined with a melanoma model utilizing B16 F1 cells expressing the immunogenic peptide glycoprotein B. We have found that the IFN- α subtypes tested have greater efficacy than IFN- α 2 in treating melanoma. The IFN subtypes delayed tumour onset, and one subtype demonstrated a significant increase in survival time. In addition, therapeutic effects could be seen when sera levels were lower than that of IFN- α 2. The *in vitro* effects of the IFN subtypes on melanoma cells was examined, uncovering differences in potency. Furthermore, we have found evidence of anti-tumour immune enhancement is associated with IFN- α therapy but not IFN- β . This research shows that the IFN- α subtypes differ in their anti-tumour efficacy, and potency of actions. Therefore the IFN- α subtypes show potential as a superior therapy in treating melanoma, which may be administered at lower, less toxic doses.

Table of Contents

DECLARATION	I
WORD COUNT	II
ABSTRACT	III
TABLE OF CONTENTS	IV
LIST OF FIGURES	VIII
LIST OF TABLES	IX
ABBREVIATIONS	X
ACKNOWLEDGEMENTS	XII
CHAPTER 1: INTRODUCTION.....	1
1.1 MELANOMA.....	1
1.1.1 <i>Biology of melanoma</i>	1
1.1.1.1 Melanocytes.....	1
1.1.1.2 Mutation.....	2
1.1.2 <i>Epidemiology and trends</i>	4
1.1.3 <i>Treatment and survival</i>	4
1.1.3.1 Surgical intervention.....	4
1.1.3.2 Chemotherapy and drugs.....	5
1.1.3.3 Immune therapies	6
1.1.4 <i>Immune response to melanoma</i>	8
1.1.4.1 Host anti-tumour mechanisms.....	8
1.1.4.2 Immune evasion	9
1.1.4.2.1 Loss of MHC class I.....	9
1.1.4.2.2 Tumour-associated antigen loss	10
1.1.4.2.3 Tumour immune modulation	10
1.2 INTERFERONS.....	11
1.2.1 <i>Type I interferons</i>	12
1.2.1.1 Interferon – α and – β	12
1.2.1.2 Type I interferon- α subtypes	14
1.2.2 <i>Production of interferon</i>	15
1.2.2.1 IFN producing cells	15

1.2.2.2	Inducers of IFN.....	16
1.2.3	<i>Interferon signaling</i>	17
1.2.3.1	Type I IFN receptor.....	17
1.2.3.2	Signal transduction.....	17
1.2.4	<i>Anti-tumour action of IFN</i>	18
1.2.4.1	Direct anti-tumour action.....	18
1.2.4.2	Enhancement of anti-tumour immunity.....	19
1.2.4.3	Enhanced innate anti-tumour action.....	20
1.2.4.4	Adaptive anti-tumour immunity.....	21
1.2.5	<i>Therapeutic applications</i>	22
1.2.5.1	Side effects.....	22
1.2.5.2	Future of type I IFN.....	23
1.3	DNA GENE THERAPY.....	24
1.3.1	<i>Immuno-gene therapy</i>	24
1.3.2	<i>Administration</i>	25
1.4	AIMS AND OBJECTIVES.....	26
1.4.1	<i>Summary</i>	26
1.4.2	<i>Hypotheses</i>	26
1.4.3	<i>Aims</i>	27
	CHAPTER 2 : MATERIALS AND METHODS	28
2.1	PREPARED BUFFERS AND SOLUTIONS.....	28
2.2	ANIMALS.....	29
2.2.1	<i>Ethics</i>	29
2.2.2	<i>Animal handling</i>	29
2.2.3	<i>Mouse strains</i>	29
2.2.3.1	Phenotyping.....	30
2.2.4	<i>Anaesthesia</i>	32
2.2.5	<i>Mapping lymph node drainage</i>	32
2.2.6	<i>Tumour inoculation</i>	32
2.2.7	<i>DNA inoculation procedure</i>	33
2.2.8	<i>Tail vein injection</i>	33
2.2.9	<i>HSV infection</i>	33
2.1.9	<i>Sera preparation</i>	34
2.3	MELANOMA CELLS.....	34
2.3.1	<i>Melanoma clones</i>	34
2.3.2	<i>Thawing cells</i>	35

2.3.3	<i>Culture and harvesting</i>	36
2.3.4	<i>Cryopreservation</i>	36
2.3.5	<i>Centrifugation and cell counting</i>	36
2.4	MOLECULAR BIOLOGY.....	37
2.4.1	<i>in vitro interferon assays</i>	37
2.4.2	<i>Interferon DNA</i>	37
2.4.3	<i>Plasmid preparation</i>	38
2.4.3.1	Restriction enzyme digest.....	39
2.4.3.2	Gel electrophoresis	39
2.5	IMMUNOLOGICAL METHODS.....	40
2.5.1	<i>ELISA</i>	40
2.5.2	<i>T cell harvesting and activation</i>	41
2.6	FLOW CYTOMETRY.....	41
2.6.1	<i>Sample preparation</i>	41
2.6.2	<i>Cell staining</i>	42
2.6.3	<i>CFSE labeling</i>	43
2.6.3.1	CD8 ⁺ T cell purification via negative selection	43
2.6.3.2	CFSE labelling of T cells and B16 F1 tumour cells	43
2.6.4	<i>GFP expression</i>	43
2.6.5	<i>Biotin-conjugation of monoclonal antibody</i>	44
2.6.6	<i>Analysis of adoptively transferred gBT.I T cells</i>	44
2.6.7	<i>MHC Class I and II</i>	45
2.6.8	<i>Apoptosis</i>	45
2.7	SOFTWARE AND STATISTICS.....	45
	CHAPTER 3: RESULTS	47
3.1	LYMPHATIC DRAINAGE OF THE SKIN AND MUSCLES.....	47
3.2	SELECTION OF A CLONAL MELANOMA LINE	50
3.2.1	<i>in vivo growth</i>	50
3.2.2	<i>MHC Class I and II</i>	51
3.2.3	<i>gB expression</i>	53
3.2.4	<i>Antigen presentation</i>	54
3.3	IFN DNA VACCINE	57
3.4	EFFICACY OF TYPE I IFN SUBTYPES TO TREAT MELANOMA <i>IN VIVO</i>	59
3.4.1	<i>Experimental plan</i>	59
3.4.2	<i>Progression of tumour during IFN treatment</i>	60

3.4.3	<i>Survival of treated mice.....</i>	63
3.4.4	<i>Tumour onset.....</i>	65
3.4.5	<i>Evident responders.....</i>	67
3.4.6	<i>IFN levels within the sera.....</i>	70
3.5	DIRECT ANTI-TUMOUR EFFECTS OF IFN <i>IN VITRO</i>	73
3.5.1	<i>MHC molecules.....</i>	73
3.5.2	<i>Inhibition of tumour growth by IFN subtypes.....</i>	76
3.5.3	<i>Induction of apoptosis by IFN subtypes.....</i>	78
3.5.4	<i>Inhibition of proliferation by IFN subtypes.....</i>	82
3.6	IMMUNE ENHANCEMENT	84
3.7	RESULTS SUMMARY	88
	CHAPTER 4: DISCUSSION	90
4.1	PROJECT SUMMARY	90
4.2	COMBINATION OF DNA IFN THERAPY WITH A MURINE MELANOMA MODEL	91
4.3	SELECTION OF A CLONAL MELANOMA LINE	93
4.4	IFN-I THERAPY AFFECTS MELANOMA GROWTH IN VIVO.....	95
4.4.1	<i>Administration of IFN.....</i>	95
4.4.2	<i>IFN-α2 and β have low efficacy in melanoma treatment.....</i>	95
4.4.3	<i>IFN-α subtypes have greater efficacy in treating melanoma.....</i>	96
4.4.4	<i>Variation within treatment groups.....</i>	97
4.4.5	<i>Level of IFN in the sera does not correlate with survival.....</i>	98
4.5	IFN-I HAVE DIRECT ANTI-TUMOUR ACTIONS <i>IN VITRO</i>	99
4.5.1	<i>IFN-I upregulates MHC class I.....</i>	99
4.5.2	<i>IFN-I induces apoptosis of melanoma cells.....</i>	100
4.5.3	<i>IFN-I decreases proliferation of melanoma cells</i>	101
4.6	IFN- α ENHANCES IMMUNE PRESSURE ON MELANOMA	102
4.7	LIMITATIONS	104
4.8	AIMS ACHIEVED.....	106
	CHAPTER 5: CONCLUSION	107
	REFERENCES	110

List of figures

Figure 1.1 Progression of melanocyte transformation.	3
Figure 1.2 Ribbon diagrams of IFN α 2 and IFN β	14
Figure 2.1: Phenotype of a negative and positive gBT.I x CD45.1 transgenic mouse.	31
Figure 3.1: Mapping lymph node drainage using Evan's Blue dye.	48
Figure 3.2 Tumour growth kinetics of B16 F1-gB clones <i>in vivo</i>	50
Figure 3.3 Upregulation of MHC class I and II in melanoma cell lines after culture with 10 ug/ml IFN γ for 48 hours.	51
Figure 3.4: Expression of green fluorescent protein in the B16 F1 parental and B16 F1 clones B6F and B10M.....	52
Figure 3.5: Response of tumour specific T cells (gBT.I) to B16 F1-gB clones <i>in vivo</i>	55
Figure 3.6: The type I IFN constructs.....	57
Figure 3.7 Experimental Plan.....	59
Figure 3.8 Growth kinetics of B16 F1-gB B10M tumours 7 days after IFN DNA therapy.	61
Figure 3.9 IFN therapy increases survival time.....	63
Figure 3.10 IFN therapy delays tumour onset	65
Figure 3.11 'Evident responders' display both delayed onset and slower tumour progression.	68
Figure 3.12 IFN levels in the sera at day 14 (21 days post DNA therapy).....	71
Figure 3.13 Expression of MHC class I and II after culture with IFN-I subtypes.	74
Figure 3.14 Culture with IFN-I alters tumour cell morphology and confluency.	76
Figure 3.15 Induction of apoptosis in tumour cells after culture with IFN-I.	80
Figure 3.16 IFN-I inhibits tumour cell proliferation.....	82
Figure 3.17 GFP expression of ex-vivo tumours from mice treated with IFN-I.....	86

List of tables

Table 2.1: Constitutes of prepared buffers	28
Table 2.2: Melanoma cell lines	35
Table 2.3: Restriction Enzymes and Buffers.....	39
Table 2.4: Antibodies used, dilution used at and manufacturer.	42
Table 3.2 Comparison of tumour onset, survival and growth between treatment groups.	67
Table 3.3 Summary of the evident responders for each treatment group	70

Abbreviations

ACT	Adoptive cell therapy
APC	Antigen presenting cell
B6	C57Bl/6J
Bcl-2	B-cell lymphoma 2 (gene)
BP	Bupivacaine
BSA	Bovine serum albumin
CFSE	Carboxyfluorescein succinimidyl ester
CpG	Cytosine—phosphate—Guanine (linear sequence)
CTL	Cytotoxic T-lymphocyte
CTLA-4	Cytotoxic T-lymphocyte antigen 4
DC	Dendritic cell
DNA	Deoxyribose nucleic acid
dsRNA	Double stranded ribonucleic acid
EDTA	Ethylenediaminetetraacetic acid
ELISA	enzyme-linked immunosorbent assay
FACS	Fluorescence-activated cell sorting
FCS	Foetal calf serum
FSC	Forward scatter
gB	Glycoprotein B
GFP	Green fluorescent protein
HEPES	hydroxyethyl piperazineethanesulfonic acid
HLA	Human leukocyte antigen (human MHC)
HSV	Herpes simplex virus
IFN	Interferon
IFN-I	Type I interferon
IFNAR	Type I IFN receptor
IgG	Immunoglobulin G
IL	Interleukin
IRES	Internal ribosome entry site
ISGs	Interferon stimulated genes

IU	International units
i.v.	intravenous
JAK	Janus Kinase
LB	Lubia Broth
LN	Lymph node
LPS	Lipopolysaccharide
MAPK	Mitogen-activated protein kinases
MHC	Major Histocompatibility Complex
MS	Multiple Sclerosis
MU	Million units
NF-kB	Nuclear factor kappa-light-chain-enhancer of activated B cells
NK	Natural killer
PAMP	Pathogen associated molecular pattern
PBS	Phosphate buffered saline
PI	Propidium Iodide
PRR	Pattern recognition receptors
RAG	Recombination activating gene
RGP	Radial growth phase
RPMI	Roswell Park Memorial Institute medium
SAV	Streptavidin
SN	Supernatant
SSC	Side scatter
ssRNA	Single stranded ribonucleic acid
STAT	Signal transducers and activators of transcription
TA	Tibialis anterior
TAE	Tris-acetate-EDTA
TLR	Toll like receptor
TRAIL	TNF-related apoptosis-inducing ligand
Tyk2	Tyrosine Kinase 2
VGP	Vertical growth phase
UV	Ultraviolet (light)

Acknowledgements

This year is definitely one I will remember. Thinking back to the start of the year, I can't believe how much I have grown, what I have learnt and the skills I have acquired since then. Of course, none of this would have been possible without the input of many people, of which I would like to personally thank a few.

I would first like to thank both my supervisors, Dr Jason Waithman and Dr Vanessa Fear. I could not have asked for more dedicated supervisors to give me guidance, and I have gained innumerable skills and knowledge from them both.

I would also like to thank Dr Elke Seppanen and Ben Wylie for always being willing to help, and showing me the ropes. An extra thank you to Elke for the many lunchtimes spent sharing her numerous stories of her life in science.

I am very grateful for having someone to share the journey with. Sarah Lacey, thank you for always being there to talk to and for your constant help. Without you, I imagine this year would have been even more terrifying!

In fact, I would like to thank *everyone* I met at the Telethon Institute, for their kindness and making me feel welcome.

A final thank you to Joe, who has supported me the entire way, through the good times and bad. And big thank you for putting up with me when I was stressed, my late nights and the rush to the train in the mornings.

I am truly grateful for everything and everyone that has been involved in this amazing journey. Thank you.